메뉴 건너뛰기




Volumn , Issue , 2011, Pages 1-33

Systemic therapy for ovarian cancer, current treatment, recent advances, and unmet needs

Author keywords

Ovarian cancer; Treatment

Indexed keywords


EID: 84891083183     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-7216-3_1     Document Type: Chapter
Times cited : (5)

References (132)
  • 1
    • 66549124405 scopus 로고    scopus 로고
    • Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
    • Aebi S, Castiglione M (2009). Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):21-23.
    • (2009) Ann Oncol , vol.20 , Issue.SUPPL. 4 , pp. 21-23
    • Aebi, S.1    Castiglione, M.2
  • 2
    • 0346423733 scopus 로고    scopus 로고
    • Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
    • Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. (1996). Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-55.
    • (1996) N Engl J Med , vol.335 , pp. 1950-1955
    • Alberts, D.S.1    Liu, P.Y.2    Hannigan, E.V.3    O'Toole, R.4    Williams, S.D.5    Young, J.A.6
  • 4
    • 49249119415 scopus 로고    scopus 로고
    • A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    • Ashworth A (2008). A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-90.
    • (2008) J Clin Oncol , vol.26 , pp. 3785-3790
    • Ashworth, A.1
  • 6
    • 49249113484 scopus 로고    scopus 로고
    • Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
    • Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. (2008). Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-14.
    • (2008) J Clin Oncol , vol.26 , pp. 3709-3714
    • Azad, N.S.1    Posadas, E.M.2    Kwitkowski, V.E.3    Steinberg, S.M.4    Jain, L.5    Annunziata, C.M.6
  • 7
    • 0034307160 scopus 로고    scopus 로고
    • BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study
    • Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. (2000). BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329-33.
    • (2000) Cancer Res , vol.60 , pp. 5329-5333
    • Baldwin, R.L.1    Nemeth, E.2    Tran, H.3    Shvartsman, H.4    Cass, I.5    Narod, S.6
  • 8
    • 68449084674 scopus 로고    scopus 로고
    • The future of targeted therapies in ovarian cancer
    • Banerjee S, Gore M (2009). The future of targeted therapies in ovarian cancer. Oncologist 14:706-16.
    • (2009) Oncologist , vol.14 , pp. 706-716
    • Banerjee, S.1    Gore, M.2
  • 9
    • 33748458411 scopus 로고    scopus 로고
    • Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group Study
    • Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. (2006). Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 102:432-39.
    • (2006) Gynecol Oncol , vol.102 , pp. 432-439
    • Bell, J.1    Brady, M.F.2    Young, R.C.3    Lage, J.4    Walker, J.L.5    Look, K.Y.6
  • 10
    • 4444383336 scopus 로고    scopus 로고
    • Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
    • Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, et al. (2004). Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22:3507-16.
    • (2004) J Clin Oncol , vol.22 , pp. 3507-3516
    • Berek, J.S.1    Taylor, P.T.2    Gordon, A.3    Cunningham, M.J.4    Finkler, N.5    Orr Jr., J.6
  • 11
    • 58549088720 scopus 로고    scopus 로고
    • Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
    • Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF (2009). Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27:418-25.
    • (2009) J Clin Oncol , vol.27 , pp. 418-425
    • Berek, J.1    Taylor, P.2    McGuire, W.3    Smith, L.M.4    Schultes, B.5    Nicodemus, C.F.6
  • 12
    • 0024522049 scopus 로고
    • Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials
    • Blackledge G, Lawton F, Redman C, Kelly K (1989). Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650-53.
    • (1989) Br J Cancer , vol.59 , pp. 650-653
    • Blackledge, G.1    Lawton, F.2    Redman, C.3    Kelly, K.4
  • 13
    • 39149127634 scopus 로고    scopus 로고
    • Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    • Blanke CD, Rankin C, Demetri GD, Ryan CW, Von Mehren M, Benjamin RS, et al. (2008). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32.
    • (2008) J Clin Oncol , vol.26 , pp. 626-632
    • Blanke, C.D.1    Rankin, C.2    Demetri, G.D.3    Ryan, C.W.4    Von Mehren, M.5    Benjamin, R.S.6
  • 14
    • 18844438857 scopus 로고    scopus 로고
    • Gemcitabine monotherapy in recurrent ovarian cancer: From the bench to the clinic
    • Bookman MA (2005). Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 15(Suppl 1):12-17.
    • (2005) Int J Gynecol Cancer , vol.15 , Issue.SUPPL. 1 , pp. 12-17
    • Bookman, M.A.1
  • 15
    • 63049115790 scopus 로고    scopus 로고
    • Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup
    • Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. (2009). Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-25.
    • (2009) J Clin Oncol , vol.27 , pp. 1419-1425
    • Bookman, M.A.1    Brady, M.F.2    McGuire, W.P.3    Harper, P.G.4    Alberts, D.S.5    Friedlander, M.6
  • 16
    • 0037440042 scopus 로고    scopus 로고
    • Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    • Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-90.
    • (2003) J Clin Oncol , vol.21 , pp. 283-290
    • Bookman, M.A.1    Darcy, K.M.2    Clarke-Pearson, D.3    Boothby, R.A.4    Horowitz, I.R.5
  • 17
    • 33750167943 scopus 로고    scopus 로고
    • Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group
    • Bookman MA, McMeekin DS, Fracasso PM (2006). Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 103:473-78.
    • (2006) Gynecol Oncol , vol.103 , pp. 473-478
    • Bookman, M.A.1    McMeekin, D.S.2    Fracasso, P.M.3
  • 18
    • 0035992369 scopus 로고    scopus 로고
    • CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup
    • Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002). CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8(7):2233-2239.
    • (2002) Clin Cancer Res , vol.8 , Issue.7 , pp. 2233-2239
    • Bowman, A.1    Gabra, H.2    Langdon, S.P.3    Lessells, A.4    Stewart, M.5    Young, A.6    Smyth, J.F.7
  • 19
    • 33750905940 scopus 로고    scopus 로고
    • Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
    • Bristow RE, Chi DS (2006). Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070-76.
    • (2006) Gynecol Oncol , vol.103 , pp. 1070-1076
    • Bristow, R.E.1    Chi, D.S.2
  • 20
    • 3042792377 scopus 로고    scopus 로고
    • Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: An Italian collaborative study from the Mario Negri Institute, Milan, G. O. N. O. (Gruppo Oncologico Nord Ovest) Group and I. O. R. (Istituto Oncologico Romagnolo) Group
    • Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, et al. (2004). Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the Mario Negri Institute, Milan, G. O. N. O. (Gruppo Oncologico Nord Ovest) Group and I. O. R. (Istituto Oncologico Romagnolo) Group. Br J Cancer 90:2112-17.
    • (2004) Br J Cancer , vol.90 , pp. 2112-2117
    • Buda, A.1    Floriani, I.2    Rossi, R.3    Colombo, N.4    Torri, V.5    Conte, P.F.6
  • 21
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
    • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165-71.
    • (2007) J Clin Oncol , vol.25 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 22
    • 36849056497 scopus 로고    scopus 로고
    • Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    • Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-86.
    • (2007) J Clin Oncol , vol.25 , pp. 5180-5186
    • Cannistra, S.A.1    Matulonis, U.A.2    Penson, R.T.3    Hambleton, J.4    Dupont, J.5    Mackey, H.6
  • 23
    • 0036498921 scopus 로고    scopus 로고
    • Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
    • Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, et al. (2002). Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232-37.
    • (2002) J Clin Oncol , vol.20 , pp. 1232-1237
    • Cantu, M.G.1    Buda, A.2    Parma, G.3    Rossi, R.4    Floriani, I.5    Bonazzi, C.6
  • 24
    • 75949084199 scopus 로고    scopus 로고
    • The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early stage high risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group Study
    • Mar
    • Chan J, Tain C, Fleming G, Monk B, Herzog T, Kapp D, et al. (2010). The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early stage high risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group Study. Gynecol Oncol Mar; 116(3):301-6.
    • (2010) Gynecol Oncol , vol.116 , Issue.3 , pp. 301-306
    • Chan, J.1    Tain, C.2    Fleming, G.3    Monk, B.4    Herzog, T.5    Kapp, D.6
  • 25
    • 41649093235 scopus 로고    scopus 로고
    • Prognostic factors for high-risk early-stage epithelial ovarian cancer: A Gynecologic Oncology Group Study
    • Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. (2008). Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer 112:2202-10.
    • (2008) Cancer , vol.112 , pp. 2202-2210
    • Chan, J.K.1    Tian, C.2    Monk, B.J.3    Herzog, T.4    Kapp, D.S.5    Bell, J.6
  • 26
    • 35348904080 scopus 로고    scopus 로고
    • Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    • Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL (2007). Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107:326-30.
    • (2007) Gynecol Oncol , vol.107 , pp. 326-330
    • Chura, J.C.1    Van Iseghem, K.2    Downs Jr., L.S.3    Carson, L.F.4    Judson, P.L.5
  • 27
    • 34548097240 scopus 로고    scopus 로고
    • AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
    • Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209-19.
    • (2007) Mol Cancer Ther , vol.6 , pp. 2209-2219
    • Davies, B.R.1    Logie, A.2    McKay, J.S.3    Martin, P.4    Steele, S.5    Jenkins, R.6
  • 30
    • 27744551640 scopus 로고    scopus 로고
    • 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd international Gynecologic Cancer Intergroup ovarian cancer consensus conference (GCIG OCCC 2004)
    • Du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. (2005). 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international Gynecologic Cancer Intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8): viii7-viii12.
    • (2005) Ann Oncol , vol.16 , Issue.SUPPL. 8
    • Du Bois, A.1    Quinn, M.2    Thigpen, T.3    Vermorken, J.4    Avall-Lundqvist, E.5    Bookman, M.6
  • 31
    • 33644966830 scopus 로고    scopus 로고
    • Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized Gynecologic Cancer Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
    • Du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, et al. (2006). Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24:1127-35.
    • (2006) J Clin Oncol , vol.24 , pp. 1127-1135
    • Du Bois, A.1    Weber, B.2    Rochon, J.3    Meier, W.4    Goupil, A.5    Olbricht, S.6
  • 32
    • 58149503624 scopus 로고    scopus 로고
    • Ixabepilone: Targeting betaIII-tubulin expression in taxane-resistant malignancies
    • Dumontet C, Jordan MA, Lee FF (2009). Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8:17-25.
    • (2009) Mol Cancer Ther , vol.8 , pp. 17-25
    • Dumontet, C.1    Jordan, M.A.2    Lee, F.F.3
  • 33
    • 17244373777 scopus 로고    scopus 로고
    • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    • Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-21.
    • (2005) Nature , vol.434 , pp. 917-921
    • Farmer, H.1    McCabe, N.2    Lord, C.J.3    Tutt, A.N.4    Johnson, D.A.5    Richardson, T.B.6
  • 34
    • 0031036177 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
    • Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. (1997). Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-92.
    • (1997) J Clin Oncol , vol.15 , pp. 187-192
    • Fennelly, D.1    Aghajanian, C.2    Shapiro, F.3    O'Flaherty, C.4    McKenzie, M.5    O'Connor, C.6
  • 35
    • 39749113438 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
    • Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890-96.
    • (2008) J Clin Oncol , vol.26 , pp. 890-896
    • Ferrandina, G.1    Ludovisi, M.2    Lorusso, D.3    Pignata, S.4    Breda, E.5    Savarese, A.6
  • 36
    • 0344393732 scopus 로고    scopus 로고
    • Strategies for reversing drug resistance
    • Fojo T, Bates S (2003). Strategies for reversing drug resistance. Oncogene 22:7512-23.
    • (2003) Oncogene , vol.22 , pp. 7512-7523
    • Fojo, T.1    Bates, S.2
  • 37
    • 0042887587 scopus 로고    scopus 로고
    • Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: A Gynecologic Group Study
    • Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS (2003). Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group Study. J Clin Oncol 21:2856-59.
    • (2003) J Clin Oncol , vol.21 , pp. 2856-2859
    • Fracasso, P.M.1    Blessing, J.A.2    Morgan, M.A.3    Sood, A.K.4    Hoffman, J.S.5
  • 38
    • 0034994444 scopus 로고    scopus 로고
    • Nucleoside analogues: Mechanisms of drug resistance and reversal strategies
    • Galmarini CM, Mackey JR, Dumontet C (2001). Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875-90.
    • (2001) Leukemia , vol.15 , pp. 875-890
    • Galmarini, C.M.1    Mackey, J.R.2    Dumontet, C.3
  • 39
    • 37849035249 scopus 로고    scopus 로고
    • Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
    • Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. (2008). Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76-82.
    • (2008) J Clin Oncol , vol.26 , pp. 76-82
    • Garcia, A.A.1    Hirte, H.2    Fleming, G.3    Yang, D.4    Tsao-Wei, D.D.5    Roman, L.6
  • 40
    • 77954091256 scopus 로고    scopus 로고
    • Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer
    • Glasspool RM, Gore M, Rustin G, et al. (2009). Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. Clin Oncol 27 (15 s, (Suppl; abstr 5562)).
    • (2009) Clin Oncol , vol.27 , Issue.15 S SUPPL. , pp. 5562
    • Glasspool, R.M.1    Gore, M.2    Rustin, G.3
  • 41
    • 45549098737 scopus 로고    scopus 로고
    • "Stemness" genomics law governs clinical behavior of human cancer: Implications for decision making in disease management
    • Glinsky GV (2008). "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol 26:2846-53.
    • (2008) J Clin Oncol , vol.26 , pp. 2846-2853
    • Glinsky, G.V.1
  • 42
    • 20044389455 scopus 로고    scopus 로고
    • Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
    • Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, et al. (2005). Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16:749-55.
    • (2005) Ann Oncol , vol.16 , pp. 749-755
    • Gonzalez-Martin, A.J.1    Calvo, E.2    Bover, I.3    Rubio, M.J.4    Arcusa, A.5    Casado, A.6
  • 43
    • 28944439741 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study
    • Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, et al. (2005). Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785-92.
    • (2005) Int J Gynecol Cancer , vol.15 , pp. 785-792
    • Gordon, A.N.1    Finkler, N.2    Edwards, R.P.3    Garcia, A.A.4    Crozier, M.5    Irwin, D.H.6
  • 44
    • 33749003463 scopus 로고    scopus 로고
    • Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
    • Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, et al. (2006). Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324-32.
    • (2006) J Clin Oncol , vol.24 , pp. 4324-4332
    • Gordon, M.S.1    Matei, D.2    Aghajanian, C.3    Matulonis, U.A.4    Brewer, M.5    Fleming, G.F.6
  • 45
    • 4644225190 scopus 로고    scopus 로고
    • Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
    • Gordon AN, Tonda M, Sun S, Rackoff W (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8.
    • (2004) Gynecol Oncol , vol.95 , pp. 1-8
    • Gordon, A.N.1    Tonda, M.2    Sun, S.3    Rackoff, W.4
  • 47
    • 0025103224 scopus 로고
    • Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
    • Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990). Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-11.
    • (1990) Gynecol Oncol , vol.36 , pp. 207-211
    • Gore, M.E.1    Fryatt, I.2    Wiltshaw, E.3    Dawson, T.4
  • 48
    • 0036137098 scopus 로고    scopus 로고
    • A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer
    • Gore M, Oza A, Rustin G, Malfetano J, Calvert H, Clarke-Pearson D, et al. (2002a). A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 38:57-63.
    • (2002) Eur J Cancer , vol.38 , pp. 57-63
    • Gore, M.1    Oza, A.2    Rustin, G.3    Malfetano, J.4    Calvert, H.5    Clarke-Pearson, D.6
  • 50
    • 34548398070 scopus 로고    scopus 로고
    • Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
    • Gossage L, Madhusudan S (2007). Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565-77.
    • (2007) Cancer Treat Rev , vol.33 , pp. 565-577
    • Gossage, L.1    Madhusudan, S.2
  • 51
    • 0037125582 scopus 로고    scopus 로고
    • Paclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial
    • Group ICON
    • Group ICON (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505-15.
    • (2002) Lancet , vol.360 , pp. 505-515
  • 52
    • 0034888639 scopus 로고    scopus 로고
    • Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - A potential mechanism for paclitaxelmediated sparing of carboplatin-induced thrombocytopenia
    • Guminski AD, Harnett PR, De Fazio A (2001). Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxelmediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 48:229-34.
    • (2001) Cancer Chemother Pharmacol , vol.48 , pp. 229-234
    • Guminski, A.D.1    Harnett, P.R.2    De Fazio, A.3
  • 53
    • 33947311852 scopus 로고    scopus 로고
    • What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    • Han ES, Monk BJ (2007). What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105:3-6.
    • (2007) Gynecol Oncol , vol.105 , pp. 3-6
    • Han, E.S.1    Monk, B.J.2
  • 54
    • 33845657404 scopus 로고    scopus 로고
    • Surgery in recurrent ovarian cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
    • Harter P, Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. (2006). Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702-10.
    • (2006) Ann Surg Oncol , vol.13 , pp. 1702-1710
    • Harter, P.1    Bois, A.2    Hahmann, M.3    Hasenburg, A.4    Burges, A.5    Loibl, S.6
  • 56
    • 33845317647 scopus 로고    scopus 로고
    • The internalization and degradation of human copper transporter 1 following cisplatin exposure
    • Holzer AK, Howell SB (2006). The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-52.
    • (2006) Cancer Res , vol.66 , pp. 10944-10952
    • Holzer, A.K.1    Howell, S.B.2
  • 57
    • 78649341233 scopus 로고    scopus 로고
    • Phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO
    • Abstract LBA5505
    • Hoskins PJ, Vergote I, Stuart G, et al. (2008). Phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol 26, Abstract LBA5505.
    • (2008) J Clin Oncol , vol.26
    • Hoskins, P.J.1    Vergote, I.2    Stuart, G.3
  • 58
    • 33947322200 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease
    • Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, et al. (2007). Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105:211-17.
    • (2007) Gynecol Oncol , vol.105 , pp. 211-217
    • Hou, J.Y.1    Kelly, M.G.2    Yu, H.3    McAlpine, J.N.4    Azodi, M.5    Rutherford, T.J.6
  • 60
    • 70349878651 scopus 로고    scopus 로고
    • Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
    • Oct 17
    • Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. (2009). Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet Oct. 17; 374(9698):1331-8.
    • (2009) Lancet , vol.374 , Issue.9698 , pp. 1331-1338
    • Katsumata, N.1    Yasuda, M.2    Takahashi, F.3    Isonishi, S.4    Jobo, T.5    Aoki, D.6
  • 61
    • 37049038819 scopus 로고    scopus 로고
    • A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
    • Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, et al. (2007). A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97:1618-24.
    • (2007) Br J Cancer , vol.97 , pp. 1618-1624
    • Krasner, C.N.1    McMeekin, D.S.2    Chan, S.3    Braly, P.S.4    Renshaw, F.G.5    Kaye, S.6
  • 62
    • 10744231732 scopus 로고    scopus 로고
    • First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
    • Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, et al. (2003). First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 13(Suppl 2):172-77.
    • (2003) Int J Gynecol Cancer , vol.13 , Issue.SUPPL. 2 , pp. 172-177
    • Kristensen, G.B.1    Vergote, I.2    Stuart, G.3    Del Campo, J.M.4    Kaern, J.5    Lopez, A.B.6
  • 63
    • 46749143864 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): A prospective randomized study - Interim results
    • abstr 5531
    • Kumar L, Hariprasas R, Kumar S (2007). Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): A prospective randomized study - Interim results. J Clin Oncol 25, abstr 5531.
    • (2007) J Clin Oncol , vol.25
    • Kumar, L.1    Hariprasas, R.2    Kumar, S.3
  • 64
    • 27844461512 scopus 로고    scopus 로고
    • Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways
    • Larue L, Bellacosa A (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24:7443-54.
    • (2005) Oncogene , vol.24 , pp. 7443-7454
    • Larue, L.1    Bellacosa, A.2
  • 65
    • 68449095803 scopus 로고    scopus 로고
    • A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)
    • Ledermann JA, Rustin GJ, Hackshaw A, Kaye SB, Jayson G, Gabra H, James LE, Bell S, Temple G (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 27, suppl; abstr 5501.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. , pp. 5501
    • Ledermann, J.A.1    Rustin, G.J.2    Hackshaw, A.3    Kaye, S.B.4    Jayson, G.5    Gabra, H.6    James, L.E.7    Bell, S.8    Temple, G.9
  • 66
    • 45749089027 scopus 로고    scopus 로고
    • Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer
    • Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. (2008). Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 26:2674-82.
    • (2008) J Clin Oncol , vol.26 , pp. 2674-2682
    • Lhomme, C.1    Joly, F.2    Walker, J.L.3    Lissoni, A.A.4    Nicoletto, M.O.5    Manikhas, G.M.6
  • 68
    • 0035865144 scopus 로고    scopus 로고
    • Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately highdose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
    • Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. (2001). Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately highdose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in smallvolume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-7.
    • (2001) J Clin Oncol , vol.19 , pp. 1001-1007
    • Markman, M.1    Bundy, B.N.2    Alberts, D.S.3    Fowler, J.M.4    Clark-Pearson, D.L.5    Carson, L.F.6
  • 69
    • 67549104877 scopus 로고    scopus 로고
    • Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
    • Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. (2009). Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114:195-98.
    • (2009) Gynecol Oncol , vol.114 , pp. 195-198
    • Markman, M.1    Liu, P.Y.2    Moon, J.3    Monk, B.J.4    Copeland, L.5    Wilczynski, S.6
  • 70
    • 0038690538 scopus 로고    scopus 로고
    • Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
    • Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. (2003). Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-65.
    • (2003) J Clin Oncol , vol.21 , pp. 2460-2465
    • Markman, M.1    Liu, P.Y.2    Wilczynski, S.3    Monk, B.4    Copeland, L.J.5    Alvarez, R.D.6
  • 71
    • 0026086870 scopus 로고
    • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
    • Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. (1991). Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-93.
    • (1991) J Clin Oncol , vol.9 , pp. 389-393
    • Markman, M.1    Rothman, R.2    Hakes, T.3    Reichman, B.4    Hoskins, W.5    Rubin, S.6
  • 72
    • 58149225750 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study
    • May 20
    • Matei D, Sill MW, De Geest K, Bristow RE (2008). Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. J Clin Oncol 26, May 20 suppl; abstr 5537.
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. , pp. 5537
    • Matei, D.1    Sill, M.W.2    De Geest, K.3    Bristow, R.E.4
  • 73
    • 73949123481 scopus 로고    scopus 로고
    • Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. (2009). Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27:5601-6.
    • (2009) J Clin Oncol , vol.27 , pp. 5601-5606
    • Matulonis, U.A.1    Berlin, S.2    Ivy, P.3    Tyburski, K.4    Krasner, C.5    Zarwan, C.6
  • 74
    • 67649364437 scopus 로고    scopus 로고
    • Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC)
    • abstract 5551
    • McGonigle KF, Muntz HG, Vuky JL, et al. (2008). Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). J Clin Oncol 26, 305s (abstract 5551).
    • (2008) J Clin Oncol , vol.26
    • McGonigle, K.F.1    Muntz, H.G.2    Vuky, J.L.3
  • 75
    • 0030054309 scopus 로고    scopus 로고
    • Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
    • McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6.
    • (1996) N Engl J Med , vol.334 , pp. 1-6
    • McGuire, W.P.1    Hoskins, W.J.2    Brady, M.F.3    Kucera, P.R.4    Partridge, E.E.5    Look, K.Y.6
  • 76
    • 34447298651 scopus 로고    scopus 로고
    • A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
    • Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, et al. (2007). A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771-76.
    • (2007) Int J Gynecol Cancer , vol.17 , pp. 771-776
    • Micha, J.P.1    Goldstein, B.H.2    Rettenmaier, M.A.3    Genesen, M.4    Graham, C.5    Bader, K.6
  • 77
    • 66849114911 scopus 로고    scopus 로고
    • Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group
    • Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. (2009). Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol 27:2686-91.
    • (2009) J Clin Oncol , vol.27 , pp. 2686-2691
    • Miller, D.S.1    Blessing, J.A.2    Krasner, C.N.3    Mannel, R.S.4    Hanjani, P.5    Pearl, M.L.6
  • 79
    • 33747088935 scopus 로고    scopus 로고
    • Long-term followup and prognostic factor analysis in clear cell adenocarcinoma of the ovary
    • Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, et al. (2006). Long-term followup and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 94:138-43.
    • (2006) J Surg Oncol , vol.94 , pp. 138-143
    • Mizuno, M.1    Kikkawa, F.2    Shibata, K.3    Kajiyama, H.4    Ino, K.5    Kawai, M.6
  • 80
    • 78649361197 scopus 로고    scopus 로고
    • A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC)
    • abstr LBA4
    • Monk J, Herzog T, Kaye S, Krasner C, Vermorken J, Muggia F, et al. (2008). A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). ESMO 33rd Congress: abstr LBA4.
    • (2008) ESMO 33rd Congress
    • Monk, J.1    Herzog, T.2    Kaye, S.3    Krasner, C.4    Vermorken, J.5    Muggia, F.6
  • 81
    • 0033986363 scopus 로고    scopus 로고
    • Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study
    • Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. (2000). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 18:106-15.
    • (2000) J Clin Oncol , vol.18 , pp. 106-115
    • Muggia, F.M.1    Braly, P.S.2    Brady, M.F.3    Sutton, G.4    Niemann, T.H.5    Lentz, S.L.6
  • 82
    • 45549099056 scopus 로고    scopus 로고
    • Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia
    • Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, et al. (2008). Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:49-55.
    • (2008) Gynecol Oncol , vol.110 , pp. 49-55
    • Nimeiri, H.S.1    Oza, A.M.2    Morgan, R.J.3    Friberg, G.4    Kasza, K.5    Faoro, L.6
  • 83
    • 0041384506 scopus 로고    scopus 로고
    • Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study
    • Omura GA, Brady MF, Look KY, Averette HE, Delmore JE, Long HJ, et al. (2003). Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study. J Clin Oncol 21:2843-48.
    • (2003) J Clin Oncol , vol.21 , pp. 2843-2848
    • Omura, G.A.1    Brady, M.F.2    Look, K.Y.3    Averette, H.E.4    Delmore, J.E.5    Long, H.J.6
  • 85
    • 0141688377 scopus 로고    scopus 로고
    • Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    • Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, De Geest K, Hartenbach EM, Baergen R (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-3200.
    • (2003) J Clin Oncol , vol.21 , Issue.17 , pp. 3194-3200
    • Ozols, R.F.1    Bundy, B.N.2    Greer, B.E.3    Fowler, J.M.4    Clarke-Pearson, D.5    Burger, R.A.6    Mannel, R.S.7    De Geest, K.8    Hartenbach, E.M.9    Baergen, R.10
  • 88
    • 0037862963 scopus 로고    scopus 로고
    • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial
    • Parmar MK, Ledermann JA, Colombo N, Du Bois A, Delaloye JF, Kristensen GB, et al. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-106.
    • (2003) Lancet , vol.361 , pp. 2099-2106
    • Parmar, M.K.1    Ledermann, J.A.2    Colombo, N.3    Du Bois, A.4    Delaloye, J.F.5    Kristensen, G.B.6
  • 89
    • 70350442636 scopus 로고    scopus 로고
    • Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the After-6 Protocol 1
    • Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. (2009). Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the After-6 Protocol 1. J Clin Oncol 27:4642-48.
    • (2009) J Clin Oncol , vol.27 , pp. 4642-4648
    • Pecorelli, S.1    Favalli, G.2    Gadducci, A.3    Katsaros, D.4    Panici, P.B.5    Carpi, A.6
  • 90
    • 33750588670 scopus 로고    scopus 로고
    • Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
    • Pfisterer J, Plante M, Vergote I, Du Bois A, Hirte H, Lacave AJ, et al. (2006). Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-707.
    • (2006) J Clin Oncol , vol.24 , pp. 4699-4707
    • Pfisterer, J.1    Plante, M.2    Vergote, I.3    Du Bois, A.4    Hirte, H.5    Lacave, A.J.6
  • 91
    • 0034600305 scopus 로고    scopus 로고
    • Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
    • Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. (2000a). Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 699-708
    • Piccart, M.J.1    Bertelsen, K.2    James, K.3    Cassidy, J.4    Mangioni, C.5    Simonsen, E.6
  • 94
    • 0034064719 scopus 로고    scopus 로고
    • Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
    • Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D et al. (2000b). Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18(6):1193-1202.
    • (2000) J Clin Oncol , vol.18 , Issue.6 , pp. 1193-1202
    • Piccart, M.J.1    Green, J.A.2    Lacave, A.J.3    Reed, N.4    Vergote, I.5    Benedetti-Panici, P.6    Bonetti, A.7    Kristeller-Tome, V.8    Fernandez, C.M.9    Curran, D.10
  • 95
    • 16444378374 scopus 로고    scopus 로고
    • Inactivation of the mitogenactivated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations
    • Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih Ie M (2005). Inactivation of the mitogenactivated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1994-2000.
    • (2005) Cancer Res , vol.65 , pp. 1994-2000
    • Pohl, G.1    Ho, C.L.2    Kurman, R.J.3    Bristow, R.4    Wang, T.L.5    Shih Ie, M.6
  • 96
    • 39549091276 scopus 로고    scopus 로고
    • Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
    • Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, et al. (2008). Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17.
    • (2008) BMC Cancer , vol.8 , pp. 17
    • Press, J.Z.1    De Luca, A.2    Boyd, N.3    Young, S.4    Troussard, A.5    Ridge, Y.6
  • 97
    • 68749121487 scopus 로고    scopus 로고
    • A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
    • abstr LBA5509
    • Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, et al. (2009). A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27, abstr LBA5509.
    • (2009) J Clin Oncol , vol.27
    • Pujade-Lauraine, E.1    Mahner, S.2    Kaern, J.3    Gebski, V.4    Heywood, M.5    Vasey, P.6
  • 98
    • 0037331627 scopus 로고    scopus 로고
    • A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group Study
    • Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, De Geest K, et al. (2003). A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 88:130-35.
    • (2003) Gynecol Oncol , vol.88 , pp. 130-135
    • Rose, P.G.1    Blessing, J.A.2    Ball, H.G.3    Hoffman, J.4    Warshal, D.5    De Geest, K.6
  • 99
    • 0031894188 scopus 로고    scopus 로고
    • Prolonged oral etoposide as secondline therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group Study
    • Rose PG, Blessing JA, Mayer AR, Homesley HD (1998). Prolonged oral etoposide as secondline therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 16:405-10.
    • (1998) J Clin Oncol , vol.16 , pp. 405-410
    • Rose, P.G.1    Blessing, J.A.2    Mayer, A.R.3    Homesley, H.D.4
  • 100
    • 37149032108 scopus 로고    scopus 로고
    • Phase 3 study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)
    • abstr LBA5529
    • Rose P, Edwards R, Finkler N, Seiden M, Duska L, Krasner C, et al. (2007). Phase 3 study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC). J Clin Oncol 25, abstr LBA5529.
    • (2007) J Clin Oncol , vol.25
    • Rose, P.1    Edwards, R.2    Finkler, N.3    Seiden, M.4    Duska, L.5    Krasner, C.6
  • 101
    • 0036407202 scopus 로고    scopus 로고
    • Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum
    • Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. (2002). Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 41:418-24.
    • (2002) Acta Oncol , vol.41 , pp. 418-424
    • Rosenberg, P.1    Andersson, H.2    Boman, K.3    Ridderheim, M.4    Sorbe, B.5    Puistola, U.6
  • 102
    • 0030039147 scopus 로고    scopus 로고
    • Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group Study
    • Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE (1996). Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7:361-64.
    • (1996) Ann Oncol , vol.7 , pp. 361-364
    • Rustin, G.J.1    Nelstrop, A.E.2    Tuxen, M.K.3    Lambert, H.E.4
  • 103
    • 68749099837 scopus 로고    scopus 로고
    • A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)
    • collaborators oboMaE
    • Rustin GJ, Van Der Burg ME, collaborators oboMaE (2009). A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol, 18 s: abstr 1.
    • (2009) J Clin Oncol , vol.18 , Issue.S , pp. 1
    • Rustin, G.J.1    Van Der Burg, M.E.2
  • 104
    • 33749600530 scopus 로고    scopus 로고
    • A multicenter, randomized, phase III study comparing paclitaxel/ carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor >1 cm after primary surgery) and IV ovarian cancer (OC)
    • Scarfone G, Scambia G, Raspagliesi F, et al. (2006). A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor >1 cm after primary surgery) and IV ovarian cancer (OC). J Clin Oncol 24, (Suppl 18S): Abstract 5003.
    • (2006) J Clin Oncol , vol.24 , Issue.SUPPL. 18S , pp. 5003
    • Scarfone, G.1    Scambia, G.2    Raspagliesi, F.3
  • 105
    • 23044511620 scopus 로고    scopus 로고
    • Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study
    • Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al. (2005). Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11:5539-48.
    • (2005) Clin Cancer Res , vol.11 , pp. 5539-5548
    • Schilder, R.J.1    Sill, M.W.2    Chen, X.3    Darcy, K.M.4    Decesare, S.L.5    Lewandowski, G.6
  • 106
    • 20144377216 scopus 로고    scopus 로고
    • Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
    • Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, et al. (2005). Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867-74.
    • (2005) J Clin Oncol , vol.23 , pp. 1867-1874
    • Sessa, C.1    De Braud, F.2    Perotti, A.3    Bauer, J.4    Curigliano, G.5    Noberasco, C.6
  • 107
    • 40949121607 scopus 로고    scopus 로고
    • ABC multidrug transporters: Structure, function and role in chemoresistance
    • Sharom FJ (2008). ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9:105-27.
    • (2008) Pharmacogenomics , vol.9 , pp. 105-127
    • Sharom, F.J.1
  • 108
    • 12844251290 scopus 로고    scopus 로고
    • Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation
    • Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. (2005). Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29:218-24.
    • (2005) Am J Surg Pathol , vol.29 , pp. 218-224
    • Singer, G.1    Stohr, R.2    Cope, L.3    Dehari, R.4    Hartmann, A.5    Cao, D.F.6
  • 109
    • 34250708027 scopus 로고    scopus 로고
    • Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients
    • Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, et al. (2007). Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13:3617-22.
    • (2007) Clin Cancer Res , vol.13 , pp. 3617-3622
    • Smyth, J.F.1    Gourley, C.2    Walker, G.3    MacKean, M.J.4    Stevenson, A.5    Williams, A.R.6
  • 110
    • 52949130732 scopus 로고    scopus 로고
    • Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1)
    • abstr 5509
    • Swart A (2007). Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). J Clin Oncol 25, abstr 5509.
    • (2007) J Clin Oncol , vol.25
    • Swart, A.1
  • 111
    • 33746625091 scopus 로고    scopus 로고
    • Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness
    • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103:11154-59.
    • (2006) Proc Natl Acad Sci USA , vol.103 , pp. 11154-11159
    • Szotek, P.P.1    Pieretti-Vanmarcke, R.2    Masiakos, P.T.3    Dinulescu, D.M.4    Connolly, D.5    Foster, R.6
  • 112
    • 0942287951 scopus 로고    scopus 로고
    • Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
    • Ten Bokkel Huinink W, Lane SR, Ross GA (2004). Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100-3.
    • (2004) Ann Oncol , vol.15 , pp. 100-103
    • Ten Bokkel Huinink, W.1    Lane, S.R.2    Ross, G.A.3
  • 113
    • 63049085227 scopus 로고    scopus 로고
    • Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer
    • Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, et al. (2009). Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 27:1426-31.
    • (2009) J Clin Oncol , vol.27 , pp. 1426-1431
    • Teneriello, M.G.1    Tseng, P.C.2    Crozier, M.3    Encarnacion, C.4    Hancock, K.5    Messing, M.J.6
  • 114
    • 36849005801 scopus 로고    scopus 로고
    • VEGF-Trap for patients (pts) with recurrent platinumresistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study
    • June 20
    • Tew WPCN, Ray-Coquard I, et al. (2007). VEGF-Trap for patients (pts) with recurrent platinumresistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I 25(18 S (June 20 Supplement):5508).
    • (2007) J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I , vol.25 , Issue.18 S SUPPL. , pp. 5508
    • Tew, W.P.C.N.1    Ray-Coquard, I.2
  • 115
    • 84900175067 scopus 로고    scopus 로고
    • Ovarian cancer: Recent developments in the standard of care and emerging options
    • Thigpen J (2009). Ovarian Cancer: Recent Developments in the Standard of Care and Emerging Options. Clinical Care Options/Oncology.
    • (2009) Clinical Care Options/Oncology
    • Thigpen, J.1
  • 116
    • 0028153230 scopus 로고
    • Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study
    • Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol 12:1748-53.
    • (1994) J Clin Oncol , vol.12 , pp. 1748-1753
    • Thigpen, J.T.1    Blessing, J.A.2    Ball, H.3    Hummel, S.J.4    Barrett, R.J.5
  • 117
    • 52649085237 scopus 로고    scopus 로고
    • Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
    • Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198-208.
    • (2008) Clin Cancer Res , vol.14 , pp. 5198-5208
    • Tothill, R.W.1    Tinker, A.V.2    George, J.3    Brown, R.4    Fox, S.B.5    Lade, S.6
  • 119
    • 0037440207 scopus 로고    scopus 로고
    • International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma
    • Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S et al. (2003). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95(2):105-112.
    • (2003) J Natl Cancer Inst , vol.95 , Issue.2 , pp. 105-112
    • Trimbos, J.B.1    Parmar, M.2    Vergote, I.3    Guthrie, D.4    Bolis, G.5    Colombo, N.6    Vermorken, J.B.7    Torri, V.8    Mangioni, C.9    Pecorelli, S.10
  • 120
    • 0028952438 scopus 로고
    • The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European organization for research and treatment of cancer
    • Van Der Burg ME, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. (1995). The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European organization for research and treatment of cancer. N Engl J Med 332:629-34.
    • (1995) N Engl J Med , vol.332 , pp. 629-634
    • Van Der Burg, M.E.1    Van Lent, M.2    Buyse, M.3    Kobierska, A.4    Colombo, N.5    Favalli, G.6
  • 121
    • 9744223515 scopus 로고    scopus 로고
    • Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
    • Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. (2004). Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-91.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 1682-1691
    • Vasey, P.A.1    Jayson, G.C.2    Gordon, A.3    Gabra, H.4    Coleman, R.5    Atkinson, R.6
  • 122
    • 65249113396 scopus 로고    scopus 로고
    • A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer
    • Vergote I, Calvert H, Kania M, Kaiser C, Zimmermann AH, Sehouli J (2009a). A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 45:1415-23.
    • (2009) Eur J Cancer , vol.45 , pp. 1415-1423
    • Vergote, I.1    Calvert, H.2    Kania, M.3    Kaiser, C.4    Zimmermann, A.H.5    Sehouli, J.6
  • 123
    • 0035915662 scopus 로고    scopus 로고
    • Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
    • Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176-82.
    • (2001) Lancet , vol.357 , pp. 176-182
    • Vergote, I.1    De Brabanter, J.2    Fyles, A.3    Bertelsen, K.4    Einhorn, N.5    Sevelda, P.6
  • 124
    • 68749089764 scopus 로고    scopus 로고
    • Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
    • Vergote I, Finkler N, Del Campo J, Lohr A, Hunter J, Matei D, et al. (2009b). Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45:2324-32.
    • (2009) Eur J Cancer , vol.45 , pp. 2324-2332
    • Vergote, I.1    Finkler, N.2    Del Campo, J.3    Lohr, A.4    Hunter, J.5    Matei, D.6
  • 125
    • 0034692452 scopus 로고    scopus 로고
    • Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
    • Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et al. (2000). Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 92:1534-5.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 1534-1535
    • Vergote, I.1    Rustin, G.J.2    Eisenhauer, E.A.3    Kristensen, G.B.4    Pujade-Lauraine, E.5    Parmar, M.K.6
  • 126
    • 58049114787 scopus 로고    scopus 로고
    • EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc-IV ovarian, fallopian tube and peritoneal cancer (ovca)
    • abstract 1767
    • Vergote I, Trope C, Amant F, Kristensen G, Sardi J, Ehlen T, et al. (2008). EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc-IV ovarian, fallopian tube and peritoneal cancer (ovca). 12th Biennial Mtg Intl Gynecol Cancer Soc. abstract 1767.
    • (2008) 12th Biennial Mtg Intl Gynecol Cancer Soc.
    • Vergote, I.1    Trope, C.2    Amant, F.3    Kristensen, G.4    Sardi, J.5    Ehlen, T.6
  • 127
    • 33947318253 scopus 로고    scopus 로고
    • Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
    • Wagner U, Du Bois A, Pfisterer J, Huober J, Loibl S, Luck HJ, et al. (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 105:132-37.
    • (2007) Gynecol Oncol , vol.105 , pp. 132-137
    • Wagner, U.1    Du Bois, A.2    Pfisterer, J.3    Huober, J.4    Loibl, S.5    Luck, H.J.6
  • 128
    • 45949109741 scopus 로고    scopus 로고
    • CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib - A trial of the PMH Phase II Consortium
    • June 20
    • Welch S, Hirte H, Elit L, et al. (2007). CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib - A trial of the PMH Phase II Consortium. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I 25(18 S (June 20 Supplement):551).
    • (2007) J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I , vol.25 , Issue.18 S SUPPL. , pp. 551
    • Welch, S.1    Hirte, H.2    Elit, L.3
  • 129
    • 84921440416 scopus 로고    scopus 로고
    • Tamoxifen for relapse of ovarian cancer
    • Mar. 17
    • Williams CJ (2001). Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2010, Mar. 17;3:CD001034.
    • (2001) Cochrane Database Syst Rev , Issue.3
    • Williams, C.J.1
  • 130
    • 34548491626 scopus 로고    scopus 로고
    • Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
    • Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621-27.
    • (2007) J Clin Oncol , vol.25 , pp. 3621-3627
    • Winter III, W.E.1    Maxwell, G.L.2    Tian, C.3    Carlson, J.W.4    Ozols, R.F.5    Rose, P.G.6
  • 131
    • 70049109804 scopus 로고    scopus 로고
    • Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
    • Jul. 8
    • Winter-Roach BA, Kitchener HC, Dickinson HO (2009). Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 2009, Jul. 8; (3): CD004706.
    • (2009) Cochrane Database Syst Rev , vol.2009 , Issue.3
    • Winter-Roach, B.A.1    Kitchener, H.C.2    Dickinson, H.O.3
  • 132
    • 25144523393 scopus 로고    scopus 로고
    • Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer
    • Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. (2005). Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422-30.
    • (2005) Clin Cancer Res , vol.11 , pp. 6422-6430
    • Zorn, K.K.1    Bonome, T.2    Gangi, L.3    Chandramouli, G.V.4    Awtrey, C.S.5    Gardner, G.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.